Compare LifeStance Health Group Inc. Common Stock (LFST) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LifeStance Health Group Inc. Common Stock vs Organon & Co. Common Stock — how do they compare? LifeStance Health Group Inc. Common Stock trades at $12.7 (market cap $4.69B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: LifeStance Health Group Inc. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while LifeStance Health Group Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold LifeStance Health Group Inc. Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| LFST | OGN | |
|---|---|---|
Market Cap | $4.69B | $3.62B |
Volume | 1,858,220 | 2,892,999 |
Sector | Health | Health |
52-Week High | $13.38 | $13.81 |
52-Week Low | $4.81 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.92B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LifeStance Health Group (LFST) trades at $12.32, down 1.28% today, with strong technical momentum showing a bullish moving average signal. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $0.06 exceeding the $0.03 forecast. Revenue growth accelerated from $1.42B in 2025 to $1.6B in 2026, while net income improved significantly from $9.66M to $51M.
Wall Street maintains strong bullish sentiment with 82% buy ratings and a $14.14 consensus price target representing 15% upside. However, elevated valuation multiples (P/E 94.8) and overbought technical conditions near 52-week highs warrant caution. The mental healthcare provider benefits from industry tailwinds but faces execution risks amid competitive pressures.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About LifeStance Health Group Inc. Common Stock
LifeStance Health provides outpatient mental healthcare, including therapy, psychiatry, and medication management services.
Read more on LFST →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
